Flavivirus Vaccine Polynucleotides Inducing Protective CD8+ T Cell Immunity
Summary
USPTO published patent application US20260097108A1 by inventors Charneau et al. disclosing recombinant polynucleotides encoding non-structural antigens from Dengue virus (DENV), Zika virus (ZIKV), and Yellow Fever virus (YFV) designed to elicit protective CD8+ T-cell immune responses. The application covers polyepitope fusion polypeptides and lentiviral vectors for flavivirus vaccine development.
What changed
USPTO published patent application US20260097108A1 disclosing polynucleotides and lentiviral vectors expressing non-structural flavivirus antigens from DENV, ZIKV, and YFV. The claimed invention utilizes MHC class I T-cell epitopes in fusion polypeptides to induce protective CD8+ T-cell immunity.
Pharmaceutical and biotechnology companies developing flavivirus vaccines should monitor this application for potential licensing opportunities or to assess freedom-to-operate. The broad claim scope covering multiple flaviviruses and polyepitope approaches may overlap with competing vaccine programs.
What to do next
- Monitor for patent prosecution updates
- Review claims for potential freedom-to-operate concerns if developing flavivirus vaccines
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
POLYNUCLEOTIDES AND LENTIVIRAL VECTORS EXPRESSING NON-STRUCTURAL ANTIGENS OF A FLAVIVIRUS SELECTED FROM THE GROUP OF DENV, ZIKV AND YFV, INDUCING PROTECTIVE CD8+ T-CELL IMMUNITY IN A HOST
Application US20260097108A1 Kind: A1 Apr 09, 2026
Inventors
Pierre CHARNEAU, Kirill NEMIROV, Pierre AUTHIE, Philippe SOUQUE, Amandine NOIRAT, Fanny MONCOQ
Abstract
The invention relates to recombinant polynucleotides encoding at least a recombinant polynucleotide expressing at least a first fusion polypeptide that comprises MHC class I T-cell epitopes suitable to elicit a T cell immune response in a host in need thereof, wherein the MHC class I T-cell epitopes originate from a plurality of antigens wherein the antigens comprise at least non-structural antigens and are from at least one flavivirus selected from the group of 10 Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV). The invention also relates to the polypeptides comprising polyepitopes of said antigens encoded by the recombinant polynucleotides.
CPC Classifications
A61K 39/12 C07K 14/70539 C12N 5/0602 C12N 7/04 C12N 15/625 C12N 15/86 A61K 2039/53 A61K 2039/70 C07K 2319/00 C12N 2740/15043 C12N 2770/24134
Filing Date
2023-10-20
Application No.
19120869
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.